Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Biomedica Plc LSE:OXB London Ordinary Share GB00BDFBVT43 ORD 50P
  Price Change % Change Share Price Shares Traded Last Trade
  2.00 0.19% 1,042.00 2,882 08:11:46
Bid Price Offer Price High Price Low Price Open Price
1,038.00 1,042.00 1,042.00 1,026.00 1,026.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 64.06 -20.89 -22.10 857
Last Trade Time Trade Type Trade Size Trade Price Currency
08:39:54 O 190 1,038.40 GBX

Oxford Biomedica (OXB) Latest News

More Oxford Biomedica News
Oxford Biomedica Investors    Oxford Biomedica Takeover Rumours

Oxford Biomedica (OXB) Discussions and Chat

Oxford Biomedica Forums and Chat

Date Time Title Posts
03/3/202108:48Feck off the_doctor12,549
02/3/202118:00Oxford Biomedica1,832
01/3/202111:11Truth Vs. Deception59
06/11/202010:41Oxford Biomedica Bulls Only Thread31,098

Add a New Thread

Oxford Biomedica (OXB) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Oxford Biomedica trades in real-time

Oxford Biomedica (OXB) Top Chat Posts

Oxford Biomedica Daily Update: Oxford Biomedica Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker OXB. The last closing price for Oxford Biomedica was 1,040p.
Oxford Biomedica Plc has a 4 week average price of 959p and a 12 week average price of 843p.
The 1 year high share price is 1,082p while the 1 year low share price is currently 366p.
There are currently 82,223,225 shares in issue and the average daily traded volume is 120,559 shares. The market capitalisation of Oxford Biomedica Plc is £855,121,540.
gareth jones: Will there be anything in The Budget tomorrow which will have a material impact on OXB? Hints of additional help for vaccine rollout. Result date now getting a little latter than previous years? No major deal announcements (predicted by year end but COVID lapses...). Share price (no advice and no expert but others are) looks ready like a coiled spring to jump up on significant news? The futures bright? The futures..
marcusl2: INVESTMENT SUMMARY Oxford Biomedica (OXB) is a global leader in lentiviral development and manufacturing. It is expanding its manufacturing facilities through Oxbox, a 84,000 sq ft state-of-the-art bioprocessing facility, significantly increasing its production capacity to match increasing demand and to continue growing its platform revenues. In the near term, revenues will continue to be driven by the Novartis partnership for CAR-T Kymriah as the commercial roll-out continues. OXB has several established development and manufacturing partnerships including Novartis, Juno Therapeutics (BMS), Bioverativ (Sanofi), Orchard Therapeutics, Sio Gene Therapies, Boehringer Ingelheim, Santen, Beam Therapeutics and PhoreMost. OXB also has a supply agreement with AstraZeneca for the large-scale commercial manufacture of the adenovirus vector-based COVID-19 vaccine AZD1222.
ehhol: OXB is in integrated company with major clients. These major clients will not be happy if one of their major rivals is looking into their kitchen. Furthermore OXB is learning from all these projects and can use the gained knowledge for themselves and/or other clients. In case for instance Sio Gene Therapies succeeds in getting the Parkinson medicine approved by FDA etc. OXB's share price will not be 10 pounds. No, I am not interested in a bid for OXB for the next couple of years.
dominiccummings: If todays share price reflect what Boris does for our share price.... he can stay away.
bountyhunter: Just after the bell for those that missed it... "Oxford, UK - 18 January, 2021: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Group"), a leading gene and cell therapy group, announces today that the Prime Minister Rt Hon Boris Johnson MP, has formally opened Oxford Biomedica's new 84,000 sq ft manufacturing facility Oxbox based in Oxford, UK. Oxbox was originally built to solely service the Group's growing demand for lentiviral vectors in the fast growing cell and gene therapy market where it is a leading global specialist working with multiple partners including Novartis, BMS and Sanofi. The Oxbox facility was completed at the end of 2019 with the Group expecting to have one or potentially two of the manufacturing suites approved during 2020. In April 2020 the Group joined the Oxford Vaccine Consortium and shortly afterwards signed the first of two agreements with AstraZeneca for COVID-19 vaccine production. By October 2020, the Group had four manufacturing suites approved by the MHRA, three of which were contracted by AstraZeneca and are currently producing bulk vaccine at 1000L scale..." Https://
gareth jones: Sunday is a day for chapel in Wales, The Sabbath, and a dry day in some counties (how the World has changed). On a serious note, again, some profit is being taken from OXB gains since March now that the vaccine has been approved. Once this is cleared the institutions will already be looking at OXB predicted balance sheet and future earnings and will act accordingly. As others have also commented M&A in Biotech companies is a big thing at the moment and US valuations continue to be in advance of UK ones. Americans also like “US” (listed) companies to invest in. The futures bright, the futures OXB? (Could OXB PR Team be sent this slogan?).
pezza51053: Okay thanks but to the layman - (me) If OXB want publicity on the back of this - then the extent of their involvement needs to be better explained ie the magic bit - otherwise they may get flak for the poor delivery I think - I will stick to the house building industry in future - but I am pleased with my OXB investment and based on your views of where the share price may go - I am a hold Cheers
bountyhunter: A reminder from the October RNS... "Oxford, UK - 6 October, 2020: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Group"), a leading gene and cell therapy group, announced today that the UK Medicines & Healthcare products Regulatory Agency (MHRA) has issued a Certificate of GMP compliance for the fourth GMP manufacturing suite within the Group's new Oxbox manufacturing facility. Oxbox is Oxford Biomedica's new 7,800 m(2) commercial manufacturing centre, located in Oxford, UK. Phase I of Oxbox is 4,200 m(2) of developed area consisting of six GMP manufacturing suites - four for viral vector production and two for fill-finish, along with warehousing, cold chain facilities and support laboratories. Construction and commissioning of Phase I was completed at the end of 2019. This approval by the MHRA follows the initial approval of the first two Oxbox suites in May 2020, and the subsequent approval of the third suite in September. This world class facility is suitable for the manufacture of a variety of viral vectors and the approval of this fourth suite completes a phase of expansion that more than doubles Oxford Biomedica's manufacturing capacity compared to 2019, supporting further growth in revenues and partner programmes. Both this suite and the suite approved in September will be operating at 1000L scale and at present will be dedicated to the manufacture of a COVID-19 viral vector vaccine candidate. Equipment for these two suites has been provided by VMIC (Vaccine Manufacturing and Innovation Centre) following the agreement signed with VMIC in June 2020."
gareth jones: Mr President, Sir. Many of my posts here are post adolescent like many other LTH’s. Names like Nom du Plumb, CFC1 remind me of early days on the thread. I accept I was a childhood genius with my early posts! On a serious note, it’s great to see the share price climbing and like others have alluded to hopefully beyond the spotlight of coronavirus vaccine manufacture the city, big pharmaceuticals will look at our “bread and butter” work in areas like Cart-T and we will be on their radar. Most of us (amateur in my case but childhood genius) on this thread believe a listing on Nasdaq would do wonders for our visibility and share price. Happy New Year to all LTH’s.
abd009: Congratulations Harry on your excellent predication of the oxb share price. I just wanted to wish you and all those who contributed all year on this very informative chat a merry Christmas and a very happy New year. Things are certainly starting to look up for oxb and who knows maybe by Christmas next year the price might yet reach £1959 which is the price I predicted in previous sweeps. There is so much to look forward to next year hopefully the astra vaccine will see off this horrible disease and this nightmare might be all over. God bless you all and my prayers goes out to all those people who are suffering around this world.
Oxford Biomedica share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Oxford Bio..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210303 08:56:46